ClinicalTrials.Veeva

Menu

Closure After Total Shoulder Arthroplasty: Prineo vs Dermabond

Montefiore Medicine Academic Health System logo

Montefiore Medicine Academic Health System

Status

Terminated

Conditions

Shoulder Arthropathy Associated With Other Conditions
Shoulder Arthritis

Treatments

Device: 2-Octyl Cyanoacrylate
Device: 2-Octyl Cyanoacrylate and Mesh

Study type

Interventional

Funder types

Other

Identifiers

NCT03899753
2018-9370

Details and patient eligibility

About

The objective is to compare two types of wound closure after total shoulder arthroplasty to determine which closure is faster, and subsequently if there are different outcomes between the two types of closures.

The objective of this study is to compare two types of wound closure after total shoulder arthroplasty procedures. A single fellowship trained shoulder surgeon will perform all procedures. It is hypothesized that participants who undergo an 2-Octyl Cyanoacrylate (OCA) mesh closure will have a faster closure time, lower cost, non-inferior complication rate, and non-inferior satisfaction scores with respect postoperative follow up and scar appearance.

Participants in the OCA mesh cohort will be compared to participants who have a closure with a running monocryl suture and dermabond. This investigation seeks to determine if OCA closure mesh closure is non-inferior to monocryl suture and dermabond in terms of operative time, cost, complications, and aesthetic appearance.

If the hypothesis is confirmed, this study will suggest that a OCA mesh closure may be used for total shoulder arthroplasty surgeries as an alternative to current conventional closures and may provide a cost benefit.

Enrollment

1 patient

Sex

All

Ages

18 to 100 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Total shoulder arthroplasty
  • Reverse total shoulder arthroplasty
  • Age 18-100
  • Single Surgeon

Exclusion criteria

  • Previous shoulder surgery
  • Known wound healing complications
  • DM, chronic steroid use, vascular insufficiency, morbid obesity (BMI>40), ESRD, family hx of pathologic scars
  • Patients on blood thinners (ASA 81mg ok)
  • Connective tissue disease
  • Allergy to skin adhesive
  • Mentally unable to complete questionnaires
  • Previous wound over planned incision

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

1 participants in 2 patient groups

2-Octyl Cyanoacrylate and mesh
Experimental group
Description:
The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
Treatment:
Device: 2-Octyl Cyanoacrylate and Mesh
2-Octyl Cyanoacrylate
Active Comparator group
Description:
The wound will be closed with just 2-Octyl Cyanoacrylate
Treatment:
Device: 2-Octyl Cyanoacrylate

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Brandon Tauberg, MD; Konrad Gruson, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems